Astellas Pharma Inc. (ALPMY) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Astellas Pharma Inc.

    OTC: ALPMY · Real-Time Price · USD
    11.48
    0.18 (1.59%)
    At close: Sep 05, 2025, 3:58 PM
    11.47
    -0.09%
    After-hours: Sep 05, 2025, 03:58 PM EDT

    Astellas Pharma Income Statement

    Financials in JPY. Fiscal year is April - March.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022 Mar 31, 2021
    Revenue
    		 1,912.3B 1,603.7B 1,518.6B 1,296.2B 1,249.5B
    Cost of Revenue
    		 349.21B 292.49B 326.79B 281.29B 269.83B
    Gross Profit
    		 1,563.1B 1,311.2B 1,191.8B 1,014.9B 979.7B
    Operating Income
    		 41.04B 25.52B 285.43B 220.02B 250.9B
    Interest Income
    		 7.87B 11.46B 5.21B 794M 683M
    Pretax Income
    		 31.24B 24.97B 131.1B 156.4B 144.85B
    Net Income
    		 50.75B 17.05B 98.71B 124.09B 120.59B
    Selling & General & Admin
    		 843.03B 740.11B 630.27B 548.84B 504.32B
    Research & Development
    		 327.65B 294.2B 276.13B 246.01B 224.49B
    Other Expenses
    		 351.39B 251.36B n/a n/a n/a
    Operating Expenses
    		 1,522.1B 1,285.7B 906.4B 794.85B 728.8B
    Interest Expense
    		 17.68B 12.01B 3.62B 4.95B 2.33B
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a n/a
    Cost & Expenses
    		 1,871.3B 1,578.2B 1,233.2B 1,076.1B 998.63B
    Income Tax Expense
    		 -19.51B 7.92B 33.65B 32.8B 24.73B
    Shares Outstanding (Basic)
    		 1.8B 1.79B 1.82B 1.85B 1.86B
    Shares Outstanding (Diluted)
    		 1.8B 1.8B 1.83B 1.85B 1.86B
    EPS (Basic)
    		 28.35 9.51 54.24 67.08 64.93
    EPS (Diluted)
    		 28.24 9.47 54.09 67.05 64.90
    EBITDA
    		 248.05B 194.81B 246.88B 241.52B 220.31B
    EBIT
    		 48.91B 36.97B 141.14B 161.84B 147.66B
    Depreciation & Amortization
    		 199.13B 157.84B 105.74B 79.68B 72.65B

    Add to Watchlist